Segment, Geographic and Other Revenue Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended				6 Months Ended
	Jun. 30, 2013		Jul. 01, 2012		Jun. 30, 2013		Jul. 01, 2012
Segment Reporting Information [Line Items]
Gains (Losses) on Sales of Assets	$ (31)	[1]	$ 0	[1]	$ 459	[1]	$ 0	[1]
Revenues	12,973		13,968		25,383		27,813
R&D Expenses	1,530	[2]	1,600	[2]	3,240	[2]	3,574	[2]
Earnings	5,357	[3]	4,180	[3]	9,082	[3]	6,359	[3]
Primary Care [Member]
Segment Reporting Information [Line Items]
Revenues	3,333	[4]	4,018	[4]	6,571	[4]	8,115	[4]
R&D Expenses	214	[4]	251	[4]	437	[4]	492	[4]
Earnings	2,071	[3],[4]	2,617	[3],[4]	4,085	[3],[4]	5,287	[3],[4]
Specialty Care And Oncology [Member]
Segment Reporting Information [Line Items]
Revenues	3,777		3,820		7,313		7,688
R&D Expenses	316		326		721		699
Earnings	2,696	[3]	2,657	[3]	5,011	[3]	5,253	[3]
Established Products and Emerging Markets [Member]
Segment Reporting Information [Line Items]
Revenues	5,000	[5]	5,301	[5]	9,772	[5]	10,401	[5]
R&D Expenses	105	[5]	66	[5]	169	[5]	139	[5]
Earnings	2,813	[3],[5]	3,076	[3],[5]	5,623	[3],[5]	6,253	[3],[5]
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	12,110		13,139		23,656		26,204
R&D Expenses	635		643		1,327		1,330
Earnings	7,580	[3]	8,350	[3]	14,719	[3]	16,793	[3]
Consumer Healthcare and other business activities [Member]
Segment Reporting Information [Line Items]
Revenues	863	[6]	829	[6]	1,727	[6]	1,609	[6]
R&D Expenses	703	[6]	694	[6]	1,379	[6]	1,389	[6]
Earnings	(453)	[3],[6]	(470)	[3],[6]	(919)	[3],[6]	(1,028)	[3],[6]
Corporate [Member]
Segment Reporting Information [Line Items]
Revenues	0	[7]	0	[7]	0	[7]	0	[7]
R&D Expenses	179	[7]	209	[7]	419	[7]	488	[7]
Earnings	(1,466)	[3],[7]	(1,589)	[3],[7]	(2,825)	[3],[7]	(3,341)	[3],[7]
Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Revenues	0	[8]	0	[8]	0	[8]	0	[8]
R&D Expenses	(1)	[8]	(2)	[8]	(2)	[8]	(3)	[8]
Earnings	(1,108)	[3],[8]	(1,153)	[3],[8]	(2,327)	[3],[8]	(2,586)	[3],[8]
Acquisition-related Costs [Member]
Segment Reporting Information [Line Items]
Revenues	0	[9]	0	[9]	0	[9]	0	[9]
R&D Expenses	0	[9]	0	[9]	0	[9]	5	[9]
Earnings	(113)	[3],[9]	(228)	[3],[9]	(203)	[3],[9]	(401)	[3],[9]
Certain significant items [Member]
Segment Reporting Information [Line Items]
Revenues	0	[10]	0	[10]	0	[10]	0	[10]
R&D Expenses	10	[10]	37	[10]	103	[10]	339	[10]
Earnings	1,012	[10],[3]	(672)	[10],[3]	924	[10],[3]	(2,732)	[10],[3]
Other unallocated [Member]
Segment Reporting Information [Line Items]
Revenues	0	[11]	0	[11]	0	[11]	0	[11]
R&D Expenses	4	[11]	19	[11]	14	[11]	26	[11]
Earnings	$ (95)	[11],[3]	$ (58)	[11],[3]	$ (287)	[11],[3]	$ (346)	[11],[3]

[1] In the first six months of 2013, represents the gain associated with the transfer of certain product rights to our equity-method investment in China. For additional information, see Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Equity-Method Investment.

[2] Excludes amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

[3] Income from continuing operations before provision for taxes on income.

[4] Revenues and Earnings from the Primary Care segment decreased in the three and six months ended June 30, 2013 as compared to the prior year, and earnings as a percentage of revenues also declined, primarily due to the loss of exclusivity for Lipitor in developed Europe and Australia and the subsequent shift in the reporting of Lipitor in those markets to the Established Products business unit, as well as the losses of exclusivity of certain other products in various markets, lower Alliance revenues from Spiriva due to the final-year terms of our co-promotion agreements in the U.S., Australia, Canada and certain European countries and the termination of the co-promotion agreement with Aricept in Japan in December 2012.

[5] Revenues and Earnings from the Established Products and Emerging Markets segment decreased in the three and six months ended June 30, 2013 as compared to the prior year, primarily due to multi-source generic competition in the U.S. for Lipitor beginning in late-May 2012, partially offset by the addition of products in certain markets that shifted to the Established Products unit from other business units beginning January 1, 2013 and strong volume growth in China. Earnings as a percentage of revenue decreased in the three and six months ended June 30, 2013 as compared to the prior year due to the change in the mix of products.

[6] Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the R&D costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

[7] Corporate for R&D expenses includes, among other things, administration expenses and compensation expenses associated with our research and development activities, and for Earnings includes, among other things, administration expenses, interest income/(expense) and certain compensation and other costs not charged to our operating segments.

[8] Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.

[9] Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives for additional information).

[10] Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the second quarter of 2013, certain significant items includes: (i) patent litigation settlement income of $1.4 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $185 million, (iii) certain asset impairment charges of $95 million and (iv) other charges of $59 million. For additional information, see Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Equity-Method Investment, Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions––Net.For Earnings in the second quarter of 2012, certain significant items includes: (i) charges for certain legal matters of $483 million, (ii) certain asset impairment charges of $77 million, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $70 million, (iv) costs associated with the separation of Zoetis of $29 million and (v) other charges of $13 million. For additional information, see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions––Net.For Earnings in the first six months of 2013, certain significant items includes: (i) patent litigation settlement income of $1.4 billion, (ii) the gain associated with the transfer of certain product rights to our equity-method investment in China of $459 million, (iii) net credits for certain legal matters of $100 million, (iv) certain asset impairment charges of $489 million, (v) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $400 million, (vi) other charges of $79 million and (vii) costs associated with the separation of Zoetis of $18 million. For additional information, see Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Equity-Method Investment, Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions––Net.For Earnings in the first six months of 2012, certain significant items includes: (i) charges for certain legal matters of $1.3 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $886 million, (iii) certain asset impairment charges of $489 million, (iv) costs associated with the separation of Zoetis of $61 million and (v) other charges of $38 million. For additional information, see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions––Net.For R&D in all periods presented, certain significant items primarily reflect additional depreciation––asset restructuring and implementation costs.

[11] Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.